Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 207, Issue 1-2, Pages 83-91Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2008.12.005
Keywords
Bone marrow stromal cells (BMSCs); Experimental autoimmune myasthenia gravis (EAMG); T helper 17 (Th17); Transforming growth factor beta (TGF-beta)
Categories
Funding
- National Natural Science Foundation of China [30770665]
- Harbin Science & Technology Bureau Creative Talent [2008RFQXS085]
- Heilongjiang Provincial Substantial Technology [GA01C02]
- National 15 High tech [2004BA745C]
- Heilongjiang Provincial Office of Science and Technology Education [10551122]
- Harbin Medical University Cell Biological Engineering Center [1151gzx05]
- Harbin Medical University Innovation Found for Postgraduates [HCXB2008001]
Ask authors/readers for more resources
Bone marrow stromal cells (BMSCs) are strong candidates for cell therapy against human autoimmune diseases. Intravenous administration of syngenic BMSCs to EAMG-model rats effectively ameliorated the disease, partially through a TGF-beta-dependent mechanism. The proliferative ability of T or B cells from EAMG rats was inhibited by BMSCs at proper cocultured ratios. And the imbalance of Th1, Th2, Th17 and Treg cell subsets accompanied with the development of EAMG was corrected by the administration of BMSCs. These results provide further insights into the pathogenesis of MG, EAMG, and other immune-mediated diseases, and support a potential role for BMSCs in their treatment. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
